Insiders CureVac N.V.

Equities

Market Closed - Nasdaq Other stock markets 01:30:00 09/05/2024 am IST			5-day change	1st Jan Change
2.88 ^USD	-3.68%		+14.29%	-31.59%

02/05	CUREVAC : A missed opportunity
26/04	UBS Cuts CureVac Price Target to $14 From $18, Maintains Buy Rating	MT

CureVac Hires New Chief Business Officer	24/04	MT
CureVac Appoints Thaminda Ramanayake as New Chief Business Officer, Effective June 1, 2024	24/04	CI
CureVac's Chief Scientific Officer Steps Down	14/23/14	MT
CureVac N.V. Announces Executive Changes	14/23/14	CI
CureVac N.V. Appoints Michael Brosnan to Supervisory Board	20/23/20	CI
Curevac N.V. Approves the Appointment of Alexander Zehnder and Myriam Mendila as Managing Directors	30/23/30	CI
CureVac's New Chief Development Officer Assumes Office	01/23/01	MT
CureVac N.V. Appoints Myriam Mendila as New Chief Development Officer	01/23/01	CI
CureVac Named as One of the World’s Most Dynamic Innovators by LexisNexis®	31/23/31	EQ
CureVac CEO to Depart in March; Sanofi Executive Named Successor	10/23/10	MT
CureVac Chief Executive Franz-Werner Haas to Step Down; Alexander Zehnder Named Successor	09/23/09	MT
CureVac N.V. Announces CEO Changes	09/23/09	CI
CureVac Announces Executive Changes	18/22/18	CI
CureVac N.V. Announces Board Changes	23/22/23	CI
Nykode Therapeutics Names CureVac Exec As New Chief Development Officer	13/22/13	MT
Novartis Exec To Join CureVac As Chief Development Officer	09/22/09	MT
CureVac N.V. Announces Changes of CDO	08/22/08	CI
CureVac Technology Chief Mariola Fotin-Mleczek to Step Down	18/22/18	MT
CureVac Announces Resignation of Mariola Fotin-Mleczek as Chief Technology Officer	17/22/17	CI
GSK names Pfizer scientist Dormitzer as vaccines R&D head	30/21/30	RE

No results for this search

CUREVAC : A missed opportunity

May 03, 2024 at 03:12 am IST